metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
la/mBC - HR-positive - 2nd line (L2) breast cancer - HR positive la/mBC - HR positive la/mBC - HR-positive - 2nd line (L2)
versus exemestane
	entinostat plus exemestane
	E2112, 2021 J Clin Oncol 2021; 39:3171-3181-. NCT02115282	RCT	la/mBC - HR-positive - 2nd line (L2)	entinostat plus exemestane	placebo plus exemestane	Women and men who had histologically confirmed invasive adenocarcinoma of the breast, metastatic or locally advanced and not amenable to local therapy with curative intent	305 / 303	low	inconclusive	inconclusive 1 % decrease in deaths (OS) (PE) inconclusive 13 % decrease in progression or deaths (PFS) (PE)
	ENCORE301, 2013 J Clin Oncol 2013; 31:2128-35-. NCT00676663	RCT	la/mBC - HR-positive - 2nd line (L2)	entinostat plus exemestane	placebo plus exemestane	Postmenopausal women with ER-positive BC who were experiencing disease relapse or progression while receiving an NSAI	64 / 66	NA	suggested	suggested 41 % decrease in deaths (OS) inconclusive 27 % decrease in progression or deaths (PFS) (PE)
	tucidinostat plus exemestane
	ACE, 2019 Lancet Oncol 2019; 20:806-815-. NCT02482753	RCT	la/mBC - HR-positive - 2nd line (L2)	tucidinostat plus exemestane	placebo plus exemestane	Postmenopausal women with HR-positive, HER2-negative, inoperable BC, whose disese relapsed after at least one endocrine therapy.	244 / 121	low	conclusif	demonstrated 25 % decrease in progression or deaths (PFS) (PE)